Canary Islands, first European destination in ROBLOX
17.1.2025 13:00:00 CET | news aktuell GmbH | Press release
Turismo de Canarias presents Find the Seasouls, an interactive experience within ROBLOX designed to promote environmental care in new generations, calling for respect for natural parks, protected spaces and the biodiversity of the islands

Canary Islands Tourism is moving into the future with the launch of Find the Seasouls, Europe's first destination experience within ROBLOX, the immersive global social platform that has more than 80 million daily active users around the world and that It is currently one of the main meeting places for the Alpha and Z generations.
Find the seasouls is an interactive experience designed to encourage care for the environment in new generations, calling for respect for natural parks, protected spaces and the biodiversity of the islands. Users travel with their avatar through the 8 Canary Islands, visiting landscapes such as the volcanoes of Lanzarote or the junipers of El Hierro, and they look for very special sea creatures, the Seasouls, characters inspired by animals that inhabit the islands. These creatures and their description have been created in collaboration with the prestigious oceanographer Cristina Fernández Gil, seeking to be faithful to the biodiversity of the Islands.
The traveler of the future learns by playing
The objective of this project is to connect with the tourist of the future (Alpha and Z generations), influencing the education of caring for the environment when visiting destinations .
Since the experience is mainly aimed at the little ones, it has been designed prioritizing values linked to sustainability and taking into account a maximum exposure time to the screen. Roblox automatically translates the video game into fourteen languages, including Spanish, English, German, French, and Portuguese.
Find the Seasouls is a project by the creative agency Flecher.co developed by Brandnewverse, subsidized by the European Regional Development Fund (ERDF).
Images

Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
They’re really going for it: emporia launches the first 5G smartphone with a screen warranty15.7.2026 08:40:22 CEST | Press release
Better safe than sorry: the emporiaSMART.8 with Smartcover and rubber protectors
FEV collaborates with Microsoft on efficient AI model approach for in car applications built on NVIDIA9.7.2026 11:05:00 CEST | Press release
Aachen – FEV is collaborating with Microsoft to integrate powerful, in-vehicle Generative AI capabilities built on NVIDIA GPU-accelerated compute and AI model microservices. The cooperation aims to enable multimodal voice, text, and gesture interactions directly in the vehicle – independent of a permanent Internet connection.
Acrobat Studio og Acrobat KI-assistent: den nye generasjonen KI-støttet produktivitet – nå også på norsk8.7.2026 15:08:48 CEST | Press release
SAN JOSE, Calif. - 8. juli 2026 - Adobe utvider tilgjengeligheten til Acrobat Studio og Acrobat KI-assistenten i Norge. Nå er de KI-støttede funksjonene for produktivitet og kreavtivitet også tilgjengelige på norsk, og kan dermed brukes av brukere på lokalt språk. Acrobat Studio kombinerer Adobe Acrobat Pro, Adobe Express Premium og smarte KI-assistenter. Acrobat KI-assistent er også tilgjengelig som et separat tillegg for alle Adobe Acrobat-produkter (Acrobat Reader, Acrobat Standard og Acrobat Pro) – et fleksibelt alternativ for alle som ønsker å bruke KI-støttede funksjoner kun når de arbeider med dokumenter. Begge disse tilbudene gjør det mulig for brukere å raskere samle inn informasjon i PDF-er og Office-dokumenter, opprette innhold og effektivisere arbeidsflyten. Acrobat Studio og Acrobat KI-assistenten markerer et viktig trinn i utviklingen av PDF-filen, som har blitt standarden for viktige dokumenter siden den ble lansert av Adobe i 1993. Acrobat utvikler seg fra et ledende pr
Grünenthal receives FDA Orphan Drug and Rare Pediatric Disease Designations for Tegacorat for the Treatment of Duchenne Muscular Dystrophy8.7.2026 10:37:04 CEST | Press release
Aachen, 08 July 2026 – Grünenthal announced today that its investigational compound tegacorat (GRM-01) received Orphan Drug and Rare Pediatric Disease Designations from the US Food and Drug Administration (FDA) for the treatment of Duchenne muscular dystrophy (DMD).
Grünenthal successfully completes Phase I trial with Nociceptin Receptor (NOP) Agonist29.6.2026 12:28:23 CEST | Press release
The investigational compound has a unique mechanism of action and the potential to become a first-in-class therapy option for the treatment of acute and chronic pain. In a Phase I trial, the investigational compound was demonstrated to be safe and well tolerated. A Phase II trial will commence later this year.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom